Literature DB >> 25237195

Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Chie Onishi1, Chie Onish1, Satomi Mori-Kimachi2, Tomohiro Hirade2, Mariko Abe2, Takeshi Taketani3, Junji Suzumiya4, Toshitsugu Sugimoto5, Seiji Yamaguchi2, Reuben Kapur6, Seiji Fukuda7.   

Abstract

Internal tandem duplication mutations in the Flt3 gene (ITD-FLT3) enhance cell migration toward the chemokine Cxcl12, which is highly expressed in the therapy-protective bone marrow niche, providing a potential mechanism underlying the poor prognosis of ITD-FLT3(+) acute myeloid leukemia. We aimed to investigate the mechanisms linking ITD-FLT3 to increased cell migration toward Cxcl12. Classification of the expression of Cxcl12-regulated genes in ITD-FLT3(+) cells demonstrated that the enhanced migration of ITD-FLT3(+) cells toward Cxcl12 was associated with the differential expression of genes downstream of Cxcl12/Cxcr4, which are functionally distinct from those expressed in ITD-FLT3(-) cells but are independent of the Cxcr4 expression levels. Among these differentially regulated genes, the expression of Rock1 in the ITD-FLT3(+) cells that migrated toward Cxcl12 was significantly higher than in ITD-FLT3(-) cells that migrated toward Cxcl12. In ITD-FLT3(-) cells, Rock1 expression and Mypt1 phosphorylation were transiently up-regulated but were subsequently down-regulated by Cxcl12. In contrast, the presence of ITD-FLT3 blocked the Cxcl12-induced down-regulation of Rock1 and early Mypt1 dephosphorylation. Likewise, the FLT3 ligand counteracted the Cxcl12-induced down-regulation of Rock1 in ITD-FLT3(-) cells, which coincided with enhanced cell migration toward Cxcl12. Rock1 antagonists or Rock1 shRNA abolished the enhanced migration of ITD-FLT3(+) cells toward Cxcl12. Our findings demonstrate that ITD-FLT3 increases cell migration toward Cxcl12 by antagonizing the down-regulation of Rock1 expression. These findings suggest that the aberrant modulation of Rock1 expression and activity induced by ITD-FLT3 may enhance acute myeloid leukemia cell chemotaxis to the therapy-protective bone marrow niche, where Cxcl12 is abundantly expressed.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CXCL12; CXCR4; Cell Biology; Gene Regulation; Hematopoiesis; ITD-Flt3; Leukemia; Rho-associated Kinase; Signal Transduction

Mesh:

Substances:

Year:  2014        PMID: 25237195      PMCID: PMC4223310          DOI: 10.1074/jbc.M114.568287

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells.

Authors:  Young H Choi; Marie D Burdick; Brett A Strieter; Borna Mehrad; Robert M Strieter
Journal:  Mol Cancer Res       Date:  2013-09-11       Impact factor: 5.852

2.  Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis.

Authors:  Seiji Fukuda; Hal E Broxmeyer; Louis M Pelus
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

3.  Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia.

Authors:  Rebecca A Moyer; Michael K Wendt; Priscilla A Johanesen; Jerrold R Turner; Michael B Dwinell
Journal:  Lab Invest       Date:  2007-06-18       Impact factor: 5.662

4.  Integration of biological networks and gene expression data using Cytoscape.

Authors:  Melissa S Cline; Michael Smoot; Ethan Cerami; Allan Kuchinsky; Nerius Landys; Chris Workman; Rowan Christmas; Iliana Avila-Campilo; Michael Creech; Benjamin Gross; Kristina Hanspers; Ruth Isserlin; Ryan Kelley; Sarah Killcoyne; Samad Lotia; Steven Maere; John Morris; Keiichiro Ono; Vuk Pavlovic; Alexander R Pico; Aditya Vailaya; Peng-Liang Wang; Annette Adler; Bruce R Conklin; Leroy Hood; Martin Kuiper; Chris Sander; Ilya Schmulevich; Benno Schwikowski; Guy J Warner; Trey Ideker; Gary D Bader
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

5.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

6.  Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2.

Authors:  Zhe Ji; Zhiqin Fan; Ying Zhang; Ronghuan Yu; Haihua Yang; Chenghua Zhou; Jia Luo; Zun-Ji Ke
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

7.  Transforming growth factor-{beta}1 modulates responses of CD34+ cord blood cells to stromal cell-derived factor-1/CXCL12.

Authors:  Sunanda Basu; Hal E Broxmeyer
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

8.  CXCR4 is a prognostic marker in acute myelogenous leukemia.

Authors:  Anke C Spoo; Michael Lübbert; William G Wierda; Jan A Burger
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

9.  CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

Authors:  Sigal Tavor; Isabelle Petit; Svetlana Porozov; Abraham Avigdor; Ayelet Dar; Leonor Leider-Trejo; Noga Shemtov; Varda Deutsch; Ella Naparstek; Arnon Nagler; Tsvee Lapidot
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

10.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

View more
  8 in total

1.  The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Authors:  M Abraham; S Klein; B Bulvik; H Wald; I D Weiss; D Olam; L Weiss; K Beider; O Eizenberg; O Wald; E Galun; A Avigdor; O Benjamini; A Nagler; Y Pereg; S Tavor; A Peled
Journal:  Leukemia       Date:  2017-03-10       Impact factor: 11.528

Review 2.  Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field.

Authors:  Andrea Duminuco; Cinzia Maugeri; Marina Parisi; Elisa Mauro; Paolo Fabio Fiumara; Valentina Randazzo; Domenico Salemi; Cecilia Agueli; Giuseppe Alberto Palumbo; Alessandra Santoro; Francesco Di Raimondo; Calogero Vetro
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

3.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

4.  Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1).

Authors:  Yoshihiro Umezawa; Hiroki Akiyama; Keigo Okada; Shinya Ishida; Ayako Nogami; Gaku Oshikawa; Tetsuya Kurosu; Osamu Miura
Journal:  J Biol Chem       Date:  2017-10-03       Impact factor: 5.157

5.  ROCK regulates the intermittent mode of interstitial T cell migration in inflamed lungs.

Authors:  Paulus Mrass; Sreenivasa Rao Oruganti; G Matthew Fricke; Justyna Tafoya; Janie R Byrum; Lihua Yang; Samantha L Hamilton; Mark J Miller; Melanie E Moses; Judy L Cannon
Journal:  Nat Commun       Date:  2017-10-18       Impact factor: 14.919

Review 6.  Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.

Authors:  Nicholas J Short; Hagop Kantarjian; Farhad Ravandi; Naval Daver
Journal:  Ther Adv Hematol       Date:  2019-02-15

7.  DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia.

Authors:  Upendarrao Golla; Melanie A Ehudin; Charyguly Annageldiyev; Zheng Zeng; Diwakar Bastihalli Tukaramrao; Anna Tarren; Abhijit A Date; Irina Elcheva; Arthur Berg; Shantu Amin; Thomas P Loughran; Mark Kester; Dhimant Desai; Sinisa Dovat; David Claxton; Arati Sharma
Journal:  Cancers (Basel)       Date:  2021-09-29       Impact factor: 6.639

Review 8.  Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure.

Authors:  Debora Capelli; Diego Menotti; Alessandro Fiorentini; Francesco Saraceni; Attilio Olivieri
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.